Effectiveness and safety of mepolizumab in the treatment of severe eosinophilic asthma

• At: Seville (Spain) (2022)
• Type: Poster
• Poster code: HPS-092
• By: ARAGóN GRACIA, Irene (Hospital Universitario Marqués de Valdecilla, Spain)
• Co-author(s): Mrs Irene Aragón Gracia, Hospital Pharmacist (Hospital Universitario Marqués de Valdecilla, santander, Spain)
  Ms Lorenzo Perez-Periañez Orrillo, Hospital Pharmacist
  Mrs Julia Sanchez Gundin, Hospital Pharmacist
  Mrs Victor Fernandez Martinez, Hospital Pharmacist
  Ms Marina Barbara Ramis Barcelo, Hospital Pharmacist
  Mrs Marta Valero Dominguez, Hospital Pharmacist
  
• Abstract:

  Background:
  Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), which targets human interleukin-5 (IL-5) with high affinity and specificity. IL-5 is the major cytokine responsible for the growth and
  differentiation, recruitment, activation and survival of eosinophils.
  
  Objectives:
  To analyse the effectiveness of mepolizumab in patients..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login